Offerings / Regulation CF / Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc.
Regulation Crowdfunding offering on StartEngine · Form C filed January 5, 2026 · Boston, Massachusetts
Repeat issuerPreferredPre-revenueCorporation, Delaware
Business summary pending extraction from the offering statement. The company is a corporation organized in Delaware on March 19, 2014, based in Boston, MA, with 2 employees and $0 of revenue in its most recent fiscal year.
Offering terms
- Security
- Series CF Preferred Stock
- Maximum
- $1,234,999.89
- Price
- $0.79 per unit
- Pricing method
- N/A
- Deadline
- April 6, 2026
- Oversubscriptions
- Accepted
- Intermediary
- StartEngine Primary, LLC
Broker-dealer, SEC file 008-70060 - Intermediary fee
- 7 - 13 percent
- Intermediary equity
- One percent (1%) of securities of the total amount of investments raised in the offering, along the same terms as investors.
Financials as filed
| Item | Most recent FY | Prior FY |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of goods sold | $0 | $0 |
| Net income (loss) | -$1,219,002 | -$1,939,043 |
| Total assets | $233,373 | $211,440 |
| Cash and equivalents | $25,466 | $7,715 |
| Accounts receivable | $0 | $0 |
| Short-term debt | $8,520,223 | $7,812,933 |
| Long-term debt | $3,898,947 | $3,628,497 |
| Taxes paid | $0 | $0 |
Two fiscal years as reported on the Form C cover sheet. 2 employees. Offered in 52 states.